Specific Electrophenotypes in Atrial Fibrillation
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 19 May 2022
- Ended
- 27 Aug 2024
- Type of study
- Observational
- Treatments tested
- Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging
- Record updated
- 12 March 2026
- Why it stopped
- Study no longer has scientific value given findings from other studies
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Suitable candidate for catheter mapping/ablation for arrhythmias or direct current cardioversion for atrial fibrillation
- Signed Informed Consent
Who cannot take part
- Severe cerebrovascular disease
- Active gastrointestinal bleeding
- Active infection or fever
- Severe uncontrolled systemic hypertension
- Congestive heart failure - NYHA Class IV
- Recent myocardial infarction
- Bleeding or clotting disorders
- Uncontrolled diabetes
- Moderate to severe renal impairment (eGFR < 30)
- Short life expectancy
- Significant anaemia
- Severe electrolyte imbalance
- Inability to receive IV or oral Anticoagulants
- Unable to give informed consent
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will investigate a common heart rhythm disturbance (arrhythmia), atrial fibrillation (AF), to improve understanding of how best to treat it in different patients. Direct current cardioversion (DCCV) is a procedure that can revert the heart to a normal rhythm, however almost all patients will only have a transient benefit, and their heart will return to the abnormal rhythm, AF. Ablation is an invasive procedure that creates scar tissue within the heart to reduce the arrhythmias, with a longer lasting effect than DCCV. It has been used with success in AF that occurs occasionally (paroxysmal) but is not as effective in AF that is more long-lasting, also known as persistent AF. Persistent AF is major cause of symptoms of breathlessness and palpitations and significantly increases the risk of stroke. Doctors are unable to accurately predict which patients will benefit most from an ablation, this can lead to as many as 50% of patients not benefitting from the procedure. The aim is to better predict which patients will benefit from an ablation. The study will include patients undergoing AF ablation or DCCV and perform additional tests including blood tests a heart MRI scan, a special type of heart tracing with up to 252 points and a short period of extra recordings from within the heart during the ablation procedure. Several techniques will be used to analyse this data, including machine learning, to develop a means predict which patients will benefit the most from the ablation procedure, without needing to use any recordings from within the heart.
Treatments tested
- Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- IdeNtification of SPecific EleCTrophenotypes in Atrial Fibrillation
- Record updated
- 12 March 2026